Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Bonn | OTHER |
| University Hospital Schleswig-Holstein | OTHER |
| Universitätsklinikum Essen | OTHER |
Not provided
Not provided
Not provided
Not provided
In the present study, a long-term cognitive follow-up of participants of the BioCog cohort (data collection period 2014 - 2019, Ethical vote No: EA2/092/14) from the Berlin study center is to be will be performed in order to record long-term cognitive sequelae (7 to 10 years after study inclusion). In addition to a medical telephone/video visit, the follow-up includes the collection of cognitive tests via web applications and questionnaires of acceptance and usability in the home environment. The study data are analysed in cooperation with the University of Bonn, University Medical Center Schleswig-Holstein and the University of Essen.
The primary research objective is the exploratory investigation of changes in cognitive test performance as well as cognitive self-care and functionality in former BioCog patients and BioCog subjects in the non-surgical comparison cohort in the long-term follow-up (7 - 10 years) compared to the baseline survey (from the BioCog main study).The primary question is operationalized in several ways:
Evaluation by Mild Cognitive Impairment Algorithm of the University Clinic Bonn (research group Prof. Wagner).
Evaluation by mild/major Neurocognitive Disorder (NCD) algorithm of Charité - University Medicine Berlin (research group Prof. Spies)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Former BioCog patients | Former BioCog patients from the Berlin study center who have undergone baseline cognitive testing and from whom plasma samples are available | ||
| Former BioCog subjects in the non-surgical comparison cohort | Former BioCog subjects in the non-surgical comparison cohort from the Berlin study center who have undergone baseline cognitive testing |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in cognitive performance | The primary object of research is the explorative investigation of the change in cognitive test performance as well as cognitive self-care and functionality in the long-term follow-up (7 - 10 years) compared to the baseline survey (from the main BioCog study). It is measured with CANTAB Research Suite, CANTAB web-based testing and paper pencil tests. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Acceptance | Acceptance of the CANTAB web-based testing of Cambridge Cognition is measured with a questionnaire. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Usability |
Not provided
Patients
Inclusion Criteria:
Exclusion Criteria:
Subjects
Inclusion Criterion:
-BioCog subjects of the non-operated comparison cohort from Berlin with cognitive testing (CANTAB Research Suite) at baseline who are contactable
Exclusion criteria:
-None
Not provided
Not provided
Not provided
Patients and subjects from the Berlin BioCog cohort.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Claudia Spies, MD, Prof. | Charitè - University Berlin | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Charité - University Medicine Berlin | Berlin | 13355 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| ID | Term |
|---|---|
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Proteomics is emerging as a vital tool in identifying biomarkers of neurodegenerative disease progression and response to therapy. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA)-Seq™ Central Nervous System Disease Panel 120 provides best-in-class sensitivity and robust, multiplexed analysis of 120 neuro-specific and inflammatory proteins from 10 µl of plasma.
Usability of the CANTAB web-based testing of Cambridge Cognition is measured with a questionnaire.
| Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| NUcleic acid Linked Immuno-Sandwich Assay Central Nervous System Disease Multiplex Panel | Analysis of 120 proteins. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| New diagnoses | Last doctor's letter/last findings (especially in the case of neurological/psychiatric/geriatric connections - e.g. memory consultation) for recording new diagnoses and recording the last outpatient and/or inpatient treatments. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Actual medication | Current comedication and supplements | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Charlson Comorbidity index | Comorbidity | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| History of Falls | History of falls is measured with the question: Have you had a fall event within the last year? | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Depression | Depression is measured with Geriatric Depression Scale. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Weight history | Weight history is measured by weight change in the past 3-6 months. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Malnutrition Universal Screening Tool (MUST)-Score | Add Scores together to calculate overall risk of malnutrition with the Malnutrition screening tool: Score 0 corresponds to low risk; Score 1 corresponds to medium risk; Score 2 or more corresponds to high risk. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Body mass index (BMI) | BMI is a calculated measure of a person's body weight (in kilograms) divided by the square of their height (in meters). | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |
| Mortality | Mortality is measured by the number of deaths. | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion |